EUVIMEDEUVIMED entdecken
Crossref

Overview of GLP-1RA Medications

Thomas A.F. Cordaro, Sumaiya A. Difaa, Amel J. Basil

Transformative Medicine · 2026

DOI: 10.54299/tmed/cdwi6557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transformative Medicine, 2026. Verfasst von Thomas A.F. Cordaro und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GLP-1 is an incretin hormone that is naturally produced in the body that regulates blood glucose and appetite. The first GLP-1RA that was FDA approved, exenatide, in 2005, originated from the Gila monster and beaded lizard, via the discovery of the exendin-4 peptide. GLP-1RAs function by mimicking endogenous GLP-1 incretin hormone, leading to an increase in glucose-dependent insulin release from beta-cells of the pancreas, decrease in glucagon release, delayed gastric emptying, and satiety. Due to the benefits seen from initiating GLP-1RAs in the market, it sparked interest in numerous studies which proved that certain GLP-1RAs can provide cardiorenal protection. The indications for GLP-1RA use have also expanded beyond diabetes and weight management. The clinical evidence that supports the use of GLP-1RAs is typically applicable to the outpatient setting, with very limited information on its use within the inpatient setting.

Zitieren

APA

Cordaro, T. A., Difaa, S. A., & Basil, A. J. (2026). Overview of GLP-1RA Medications. Transformative Medicine. https://doi.org/10.54299/tmed/cdwi6557

Vancouver

Cordaro TA, Difaa SA, Basil AJ. Overview of GLP-1RA Medications. Transformative Medicine. 2026. doi:10.54299/tmed/cdwi6557

BibTeX
@article{Cordaro2026,
  author = {Cordaro, Thomas A.F. and Difaa, Sumaiya A. and Basil, Amel J.},
  title = {Overview of GLP-1RA Medications},
  journal = {Transformative Medicine},
  year = {2026},
  doi = {10.54299/tmed/cdwi6557}
}
Kostenlos starten →